ADPT vs GRAL
ADPT: Adaptive Biotechnologies leverages proprietary immune medicine and sequencing technologies to transform disease diagnosis and drug development, with commercial focus on minimal residual disease testing and TCR-antigen discovery. GRAL: GRAIL is developing Galleri, a blood-based multi-cancer early detection test designed to detect many types of cancer from a single draw and pinpoint the tissue of origin, pending FDA approval.
Side-by-side fundamentals
| Metric | ADPT | GRAL | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $21.95 | $70.66 | |
| Market cap as of 2026-07-23 | $3.5B | $3.0B | |
| Net margin as of 2026-07-23 | -16.8% | -253.2% | ADPT higher |
| Gross margin as of 2026-07-23 | +75.3% | +49.3% | ADPT higher |
| Operating margin as of 2026-07-23 | -15.8% | -348.7% | ADPT higher |
| ROE as of 2026-07-23 | -24.3% | -16.4% | GRAL higher |
| ROA as of 2026-07-23 | -9.9% | -14.3% | ADPT higher |
| Debt / equity as of 2026-07-23 | 0.60 | 0.00 | GRAL lower |
| Revenue growth (YoY) as of 2026-07-23 | +55.9% | +19.4% | ADPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.3% | +25.7% | GRAL higher |
| Beta as of 2026-07-23 | 2.10 | 2.25 | |
| 1-year return as of 2026-07-22 close | +119.0% | +111.7% | ADPT higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.